NTrans Technologies specializes in non-viral delivery platforms for cell and gene therapies. The company focuses on delivering therapies to specific cells and tissues by leveraging natural mechanisms for cellular uptake.

NTrans Technologies

NTrans Technologies BV | 832 followers on LinkedIn. Natural delivery to unlock the full potential of cell and gene therapies | Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues.

We leverage nature’s own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery.

CEO and co-founder of Predica Diagnostics BV

Marco De Boer (Ph.D., MBA)

CEO NTrans Technologies | Innovation Management | Life Sciences

Ester Weijers

Research Technician

Yali Gal-On

Senior Scientist at Ntrans technologies

Camilo F Muñoz Segovia

NTrans Technologies BV

We were honored to welcome the Mayor of Leiden Peter Heijkoop to NTrans Technologies at our location in the Leiden BioScience Park, housed in the vibrant ecosystem of Biopartner. This esteemed visit reinforces the dynamic connections between innovative companies and local leadership within our community. The Mayor’s engagement and enthusiasm for the Leiden BioScience Park is inspiring, showcasing a shared vision for advancing science and innovation in our region. His interest in NTrans Technologies reflects the growing support for groundbreaking research and entrepreneurial spirit in the life sciences sector. During the visit, our CEO Ester Weijers had the opportunity to pitch our latest developments, followed by an insightful lab tour. We appreciated the thought-provoking questions he asked, which truly reflect his commitment to understanding and supporting our field. Thank you to the Mayor for a memorable visit, and for his continued support of innovation in Leiden! #Leiden #LeidenBioSciencePark #Biopartner #NTransTechnologies #Biotech #ResearchAndInnovation #ScientificInnovation #LifeSciences

We are excited to share that EUR 10 million have been awarded to NecstGen , NTrans Technologies BV , Leiden University Medical Center , and Divvly to transform Cell and Gene Therapies through the IPCEI Med4Health program. This significant funding will drive our efforts to transform the production of cell and gene therapies, making these life-saving treatments more accessible and affordable for patients in need. Read more about this collaborative effort here: https://lnkd.in/eaURZiu3 #celltherapy #genetherapy #biotechinnovation #CGT #IPCEI

We are searching for talent! We are currently searching for an enthusiastic research technician - molecular biology to join our team. If you have any questions please don't hesitate to ask. #hiring #HLO #LifeSciences #NTransTechnologies #vacancy #carreers

NTrans Technologies participates in BIO-Europe Spring 2024 on 18-20 March in Barcelona. BIO-Europe Spring 2024 is a key event in making connections and building partnerships in the global biopharma community. NTrans looks forward to engaging in meaningful discussions and establishing new partnerships. NTrans Technologies BV developed a non-viral delivery platform for cell and gene therapies building upon CRISPR technology. With our delivery platform we aim to solve a critical bottleneck: safe and scalable delivery of gene-editing therapies.

We're excited to announce the launch of NTrans Technologies brand-new website and visual identity! At NTrans, we are committed to tackling a critical challenge in cell and gene therapy: delivering the gene-editing complex effectively. We prioritize excellence and innovation in our daily endeavors, so that we can make a positive impact for those living with serious diseases. Discover our latest news and learn more about our innovative delivery platform on https://lnkd.in/d_cTYqEF #NTranstechnologies #Websitelaunch #Healthcare #cellandgenetherapy

Microsoft Exchange Online

DMARC

Office 365 Mail

Microsoft Azure DNS

Gravatar Profiles

Junior Scientist

Sebastiaan Kuiper

Marco De Boer

CEO and Co-Founder

Europe Wellness Companies (Top 10K)

Private The Netherlands Companies (Top 10K)

Biotechnology Companies (Top 10K)

European Union (EU) Companies With Fewer Than 10 Employees (Top 10K)

NTrans Technologies offers a proprietary platform technology for the intracellular delivery of bioactive molecules.

The company is further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use. NTrans Technologies' goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.


Venture Round - NTrans Technologies

Utrecht

The Netherlands

Europe

Bangladesh

Asia

Hungary

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 2:34 PM	7361fe1d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 2:34 PM	f89e092c
crunchbase trigger	general	Nov 19, 2024 2:34 PM	2be67fdc
crunchbase profile	general	Nov 20, 2024 4:49 AM	ca1bc252
li profile	general	Nov 19, 2024 2:34 PM	26e345c0
translate crunchbase fundingrounds	general	Nov 20, 2024 5:35 AM	4b43410e
peers	general	Nov 19, 2024 2:34 PM	a17465ad
news basic	general	Nov 19, 2024 2:34 PM	ba03b9c7
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

NTRA

COM:NTRANSTECHNOLOGIES

NTrans Technologies